256 related articles for article (PubMed ID: 26329815)
1. The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
Gershman B; Moreira DM; Tollefson MK; Frank I; Cheville JC; Thapa P; Tarrell RF; Thompson RH; Boorjian SA
Urol Oncol; 2016 Jan; 34(1):4.e1-9. PubMed ID: 26329815
[TBL] [Abstract][Full Text] [Related]
2. ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder.
D'Andrea D; Moschini M; Soria F; Gust KM; Briganti A; Karakiewicz PI; RouprĂȘt M; Shariat SF
Anticancer Res; 2017 Oct; 37(10):5747-5753. PubMed ID: 28982896
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK
Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414
[TBL] [Abstract][Full Text] [Related]
4. The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy.
Liu J; Dai Y; Zhou F; Long Z; Li Y; Liu B; Xie D; Tang J; Tan J; Yao K; Zhang Y; Tang Y; He L
Urol Oncol; 2016 Nov; 34(11):484.e1-484.e8. PubMed ID: 27341738
[TBL] [Abstract][Full Text] [Related]
5. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy.
Linder BJ; Frank I; Cheville JC; Tollefson MK; Thompson RH; Tarrell RF; Thapa P; Boorjian SA
Eur Urol; 2013 May; 63(5):839-45. PubMed ID: 23332883
[TBL] [Abstract][Full Text] [Related]
6. Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes.
Mason RJ; Frank I; Bhindi B; Tollefson MK; Thompson RH; Karnes RJ; Tarrell R; Thapa P; Boorjian SA
World J Urol; 2017 Dec; 35(12):1879-1884. PubMed ID: 28913657
[TBL] [Abstract][Full Text] [Related]
7. Oncologic outcomes following robot-assisted radical cystectomy with minimum 5-year follow-up: the Roswell Park cancer institute experience.
Raza SJ; Al-Daghmin A; Zhuo S; Mehboob Z; Wang K; Wilding G; Kauffman E; Guru KA
Eur Urol; 2014 Nov; 66(5):920-8. PubMed ID: 24768522
[TBL] [Abstract][Full Text] [Related]
8. Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
Kluth LA; Xylinas E; Rieken M; El Ghouayel M; Sun M; Karakiewicz PI; Lotan Y; Chun FK; Boorjian SA; Lee RK; Briganti A; RouprĂȘt M; Fisch M; Scherr DS; Shariat SF
BJU Int; 2014 Mar; 113(3):393-8. PubMed ID: 24053618
[TBL] [Abstract][Full Text] [Related]
9. Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy.
Klatte T; Xylinas E; Rieken M; RouprĂȘt M; Fajkovic H; Seitz C; Karakiewicz PI; Lotan Y; Babjuk M; de Martino M; Shariat SF
Urol Oncol; 2014 Jul; 32(5):625-30. PubMed ID: 24495451
[TBL] [Abstract][Full Text] [Related]
10. Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality?
Abel EJ; Linder BJ; Bauman TM; Bauer RM; Thompson RH; Thapa P; Devon ON; Tarrell RF; Frank I; Jarrard DF; Downs TM; Boorjian SA
Eur Urol; 2014 Dec; 66(6):1139-47. PubMed ID: 25194909
[TBL] [Abstract][Full Text] [Related]
11. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
12. The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy.
Engel O; Soave A; Peine S; Kluth LA; Schmid M; Shariat SF; Dahlem R; Fisch M; Rink M
World J Urol; 2015 Nov; 33(11):1769-76. PubMed ID: 25782867
[TBL] [Abstract][Full Text] [Related]
13. Risk factors and outcomes of urethral recurrence following radical cystectomy.
Boorjian SA; Kim SP; Weight CJ; Cheville JC; Thapa P; Frank I
Eur Urol; 2011 Dec; 60(6):1266-72. PubMed ID: 21871713
[TBL] [Abstract][Full Text] [Related]
14. Oncological Outcomes in Patients Treated with Radical Cystectomy for Bladder Cancer: Comparison Between Open, Laparoscopic, and Robot-Assisted Approaches.
Kim TH; Sung HH; Jeon HG; Seo SI; Jeon SS; Lee HM; Choi HY; Jeong BC
J Endourol; 2016 Jul; 30(7):783-91. PubMed ID: 27055782
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
[TBL] [Abstract][Full Text] [Related]
16. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.
Moschini M; Sharma V; Dell'oglio P; Cucchiara V; Gandaglia G; Cantiello F; Zattoni F; Pellucchi F; Briganti A; Damiano R; Montorsi F; Salonia A; Colombo R
BJU Int; 2016 Apr; 117(4):604-10. PubMed ID: 25851271
[TBL] [Abstract][Full Text] [Related]
17. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making.
Aziz A; Shariat SF; Roghmann F; Brookman-May S; Stief CG; Rink M; Chun FK; Fisch M; Novotny V; Froehner M; Wirth MP; Schnabel MJ; Fritsche HM; Burger M; Pycha A; Brisuda A; Babjuk M; Vallo S; Haferkamp A; Roigas J; Noldus J; Stredele R; Volkmer B; Bastian PJ; Xylinas E; May M
BJU Int; 2016 Feb; 117(2):272-9. PubMed ID: 25381844
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing the length of stay after radical cystectomy: implications for cancer care and perioperative management.
Pietzak EJ; Hwang WT; Malkowicz SB; Guzzo TJ
Ann Surg Oncol; 2014 Dec; 21(13):4383-9. PubMed ID: 25047468
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
20. Restrictive transfusion in radical cystectomy is safe.
Syan-Bhanvadia S; Drangsholt S; Shah S; Cai J; Miranda G; Djaladat H; Daneshmand S
Urol Oncol; 2017 Aug; 35(8):528.e15-528.e21. PubMed ID: 28476526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]